Symposia: Multiple Myeloma: Pharmacologic Therapies
Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Clinical trials, Combination therapy, Adult, Drug development, Bispecific Antibody Therapy, Elderly, Clinical Research, Plasma Cell Disorders, Diseases, Treatment Considerations, Biological therapies, Immunotherapy, Lymphoid Malignancies, Adverse Events, Study Population, Human, Measurable Residual Disease
Type: Oral
Hematology Disease Topics & Pathways:
Research, Clinical trials, Combination therapy, Adult, Drug development, Bispecific Antibody Therapy, Elderly, Clinical Research, Plasma Cell Disorders, Diseases, Treatment Considerations, Biological therapies, Immunotherapy, Lymphoid Malignancies, Adverse Events, Study Population, Human, Measurable Residual Disease
Monday, December 9, 2024: 4:30 PM-6:00 PM
Hall B
(San Diego Convention Center)
Moderators:
Alissa Visram, MD, MPH,
and
Hamza Sloan Hashmi, MD,
Disclosures:
Visram: GSK: Honoraria; Janssen: Honoraria, Research Funding; BMS: Honoraria, Research Funding; Forus Therapeutics: Honoraria; Amgen: Honoraria; Takeda: Honoraria; Sanofi: Honoraria.
This Session Brings Phase 1 and Phase 2 Trials Introducing Drugs with New Mechanism of Action or New Combinations Being Disclosed For the First Time in Multiple Myeloma. The Session Contains New Immunotherapy Antibodies, Combinations with Bispecific T-Cell Engagers, Combinations with New CELMoDs and First Data Disclosure of Agents Exploring New Targets in Relapsed and Refractory Multiple Myeloma.
4:30 PM
4:45 PM
5:00 PM
5:15 PM
5:30 PM
5:45 PM
See more of: Oral and Poster Abstracts
*signifies non-member of ASH